TY - JOUR
T1 - Antimicrobial and antiinflammatory treatment of Bacterial meningitis
AU - Saez-Llorens, X.
AU - McCracken G.H., Jr
PY - 1999
Y1 - 1999
N2 - Mortality and morbidity rates of bacterial meningitis are still unacceptably high, and thus, new, potent antimicrobial agents and adjuvant anti-inflammatory strategies are being evaluated to improve patient outcome. With the declining rates of Haemophilus influenzae type B infections, after the introduction of conjugated vaccines, research to find preventive measures for Streptococcus pneumoniae and Neisseria meningitidis infections is underway. In the meantime, scientific effort is being directed optimally to treat disease caused by multiresistant pneumococcal strains.
AB - Mortality and morbidity rates of bacterial meningitis are still unacceptably high, and thus, new, potent antimicrobial agents and adjuvant anti-inflammatory strategies are being evaluated to improve patient outcome. With the declining rates of Haemophilus influenzae type B infections, after the introduction of conjugated vaccines, research to find preventive measures for Streptococcus pneumoniae and Neisseria meningitidis infections is underway. In the meantime, scientific effort is being directed optimally to treat disease caused by multiresistant pneumococcal strains.
UR - http://www.scopus.com/inward/record.url?scp=0032770691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032770691&partnerID=8YFLogxK
U2 - 10.1016/S0891-5520(05)70097-0
DO - 10.1016/S0891-5520(05)70097-0
M3 - Article
C2 - 10470558
AN - SCOPUS:0032770691
SN - 0891-5520
VL - 13
SP - 619
EP - 636
JO - Infectious disease clinics of North America
JF - Infectious disease clinics of North America
IS - 3
ER -